Table 5.
Total and cause-specific mortality for prevalent RA-ILD compared with RA patients without ILD (n = 509 787)
| Group | Unadjusted HR (95% CI) for total mortality | Unadjusted sdHR (95% CI) for cardiovascular mortality | Unadjusted sdHR (95% CI) for cancer mortality | Unadjusted sdHR (95% CI) for respiratory mortality | Unadjusted sdHR (95% CI) for infection mortality | Unadjusted sdHR (95% CI) for other mortality |
|---|---|---|---|---|---|---|
| RA without ILD | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| RA-ILD | 2.36 (2.28, 2.45) | 1.42 (1.32, 1.54) | 2.08 (1.90, 2.27) | 7.08 (6.67, 7.51) | 1.89 (1.55, 2.30) | 1.78 (1.66, 1.90) |
| Group | Multivariable* HR (95% CI) for total mortality | Multivariable* sdHR (95% CI) for cardiovascular mortality | Multivariable* sdHR (95% CI) for cancer mortality | Multivariable* sdHR (95% CI) for respiratory mortality | Multivariable* sdHR (95% CI) for infection mortality | Multivariable* sdHR (95% CI) for other mortality |
|---|---|---|---|---|---|---|
| RA without ILD | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) | 1.00 (Ref) |
| RA-ILD | 1.66 (1.60, 1.72) | 1.01 (0.93, 1.09) | 1.56 (1.43, 1.71) | 4.39 (4.13, 4.67) | 1.19 (0.97, 1.45) | 1.30 (1.21, 1.40) |
*
Adjusted for age, sex, US region, smoking, MTX use, HCQ use, TNF inhibitor use, other bDMARD or tsDMARD use, glucocorticoid use, combined comorbidity score and number of physician visits.